Cargando…
Pharmacogenetic Study on the Effect of Rivastigmine on PS2 and APOE Genes in Iranian Alzheimer Patients
BACKGROUND/AIMS: Alzheimer disease (AD) is a complex and genetically heterogeneous disorder, and certain genes such as PS2 and APOE4 contribute to the development of AD. Due to its heterogeneity, AD-predisposing genes could vary in different populations. Moreover, not all AD patients will respond to...
Autores principales: | Zamani, M., Mehri, M., Kollaee, A., Yenki, P., Ghaffarpor, M., Harirchian, M.H., Shahbazi, M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
S. Karger AG
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3199882/ https://www.ncbi.nlm.nih.gov/pubmed/22163243 http://dx.doi.org/10.1159/000329514 |
Ejemplares similares
-
Rivastigmine in the treatment of Alzheimer’s disease: an update
por: Onor, Maria Luisa, et al.
Publicado: (2007) -
Rivastigmine in the treatment of patients with Alzheimer’s disease
por: Müller, Thomas
Publicado: (2007) -
Lipoprotein Lipase HindIII Intronic Polymorphism in a Subset of Iranian Patients with Late-Onset Alzheimer’s Disease
por: Sayad, Azadeh, et al.
Publicado: (2012) -
Once-daily transdermal rivastigmine in the treatment of Alzheimer’s disease
por: Wentrup, Andreas, et al.
Publicado: (2009) -
The Association between Sporadic Alzheimer’s Disease and the Human ABCA1 and APOE Gene Polymorphisms in Iranian Population
por: Khorram Khorshid, H R, et al.
Publicado: (2011)